Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Cash & Equivalents (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Cash & Equivalents readings, the most recent being $16.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 1.29% year-over-year to $16.0 million, compared with a TTM value of $16.0 million through Dec 2025, down 1.29%, and an annual FY2025 reading of $16.0 million, down 1.29% over the prior year.
  • Cash & Equivalents hit $16.0 million in Q4 2025 for Lisata Therapeutics, down from $19.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $32.4 million in Q3 2023, with the low at $12.1 million in Q2 2025.
  • Median Cash & Equivalents over the past 3 years was $19.8 million (2023), compared with a mean of $20.4 million.
  • The sharpest move saw Cash & Equivalents skyrocketed 45.26% in 2024, then tumbled 57.17% in 2025.
  • Year by year, Cash & Equivalents stood at $22.6 million in 2023, then dropped by 28.26% to $16.2 million in 2024, then dropped by 1.29% to $16.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $16.0 million, $19.0 million, and $12.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.